Studies of GLP-1 treatment around bariatric surgery cover several reasons for using a medication. The studies here started at least one year after surgery. Some enrolled people who had regained weight, while others included people whose initial weight loss fell short [1].
How much weight did people lose after starting medication?
The review included 27 papers. Nineteen contributed to at least one pooled analysis. At 12 months of medication, average weight loss was 9.22% with liraglutide and 9.02% with semaglutide [1]. Those estimates came from separate groups of studies. The averages do not establish which drug works better for the same patients.
Two studies compared tirzepatide with semaglutide. At six months, the pooled difference favored tirzepatide by 4.23 percentage points (95% CI 1.42 to 7.05) [1]. The treatment doses differed across studies. That limits what the comparison can tell us about other doses or longer treatment.
What did a trial after gastric bypass find?
One trial randomized 132 adults who had regained weight after Roux-en-Y gastric bypass. Both groups received lifestyle counseling. At 56 weeks, weight was down 8.8% with liraglutide and up 1.1% with placebo among those with outcome data [2]. Many participants did not complete treatment. The trial focused on one operation and does not establish results after other procedures.
What is still uncertain?
The review found mostly digestive side effects among those reported. It did not report serious adverse events attributed to the medicines, but adverse-event reporting was incomplete [1]. The evidence also does not show that medication gives the same results as a second operation. A bariatric team can review weight regain and discuss which options fit the patient’s anatomy and health.